Medical School: Hebrew University, Jerusalem, Israel
Residency: The Chaim Sheba Medical Center, Tel-Hashomer, Israel
Fellowship: University of Toronto, Toronto, Ontario, Canada

https://www.ensol-therapies.com/

Dr Rubinstein holds several issued and pending US and international patents and has authored more than 200 peer-reviewed scientific papers. He is Editor-in-Chief, Nanotechnology, Science and Applications, Clinical Editor, Nanomedicine: Nanotechnology, Biology and Medicine and Associate Editor, International Journal of Nanomedicine. Dr. Rubinstein co-founded ResQ Pharma, Inc. that has recently submitted an IND application to the US FDA, and EnSol Therapeutics, LLC. Dr. Rubinstein is Board Member and Director of Advanced Life Sciences, a publicly-traded biopharmaceutical company in Woodridge, Illinois, USA.